NotI Microarrays: Novel Epigenetic Markers for Early Detection and Prognosis of High Grade Serous Ovarian Cancer

International Journal of Molecular Sciences

Vladimir Kashuba³  Alexey A. Dmitriev⁴  George S. Krasnov⁴  Tatiana Pavlova³  Ilya Ignatjev³  Vasily V. Gordiyuk⁵  Anna V. Gerashchenko⁵  Eleonora A. Braga²  Surya P. Yenamandra³  Michael Lerman¹  Vera N. Senchenko⁴ 

[1] Affina Biotechnologies, Stamford, CT 06902, USA; E-Mail:;Russian State Genetics Center GosNIIgenetika, Moscow 117545, Russia; E-Mail:;Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm SE-171 77, Sweden; E-Mails:;Laboratory of Structural and Functional Genomics, Engelhard Institute of Molecular Biology, Russian Academy of Science, Moscow 119991, Russia; E-Mails:;Department of Molecular Oncogenetics, Institute of Molecular Biology and Genetics, NASU, Kiev 01000, Ukraine; E-Mails:

关键词: ovarian cancer;    biomarkers;    NotI microarrays;    epigenetics;    early detection of ovarian cancer;    prognosis of ovarian cancer;   

DOI  :  10.3390/ijms131013352

来源: mdpi

【 摘 要 】

Chromosome 3-specific NotI microarray (NMA) containing 180 clones with 188 genes was used in the study to analyze 18 high grade serous ovarian cancer (HGSOC) samples and 7 benign ovarian tumors. We aimed to find novel methylation-dependent biomarkers for early detection and prognosis of HGSOC. Thirty five NotI markers showed frequency of methylation/deletion more or equal to 17%. To check the results of NMA hybridizations several samples for four genes (LRRC3B, THRB, ITGA9 and RBSP3 (CTDSPL)) were bisulfite sequenced and confirmed the results of NMA hybridization. A set of eight biomarkers: NKIRAS1/RPL15, THRB, RBPS3 (CTDSPL), IQSEC1, NBEAL2, ZIC4, LOC285205 and FOXP1, was identified as the most prominent set capable to detect both early and late stages of ovarian cancer. Sensitivity of this set is equal to (72 ± 11)% and specificity (94 ± 5)%. Early stages represented the most complicated cases for detection. To distinguish between Stages I + II and Stages III + IV of ovarian cancer the most perspective set of biomarkers would include LOC285205, CGGBP1, EPHB1 and NKIRAS1/RPL15. The sensitivity of the set is equal to (80 ± 13)% and the specificity is (88 ± 12)%. Using this technique we plan to validate this panel with new epithelial ovarian cancer samples and add markers from other chromosomes.

【 授权许可】

CC BY   
© 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.